Catabasis Pharmaceuticals


Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial for edasalonexent is enrolling boys affected by Duchenne .
In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values .
In January 2020, Catabasis announced the pricing of an underwritten public offering of 4,600,000 shares of common stock priced at $5.00 per share. The gross proceeds are expected to be approximately $23 million, before deducting the underwriting discount and other offering expenses.